Groupon And Bionano Genomics On The List Of Winners And Losers Of Monday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Groupon, ImmunoGen, and Inovio Pharmaceuticals.

Rank Financial Asset Price Change Updated (EST)
1 Groupon (GRPN) 4.18 11.33% 2023-04-17 13:55:06
2 ImmunoGen (IMGN) 4.36 7.8% 2023-04-17 13:55:27
3 Inovio Pharmaceuticals (INO) 0.91 7.1% 2023-04-17 13:25:30
4 Enphase Energy (ENPH) 223.52 7% 2023-04-17 13:54:12
5 Viking Therapeutics (VKTX) 20.00 6.67% 2023-04-17 14:00:49
6 Nikola (NKLA) 0.87 6.6% 2023-04-17 13:44:40
7 M&T Bank (MTB) 124.25 6.57% 2023-04-17 13:42:55
8 Li Auto (LI) 26.08 6.19% 2023-04-17 13:59:31
9 Nio (NIO) 9.81 5.77% 2023-04-17 13:43:04
10 Momo (MOMO) 9.22 5.68% 2023-04-17 13:26:08

The three biggest losers today are Bionano Genomics, State Street Corporation, and Moderna.

Rank Financial Asset Price Change Updated (EST)
1 Bionano Genomics (BNGO) 0.90 -17.75% 2023-04-17 13:28:42
2 State Street Corporation (STT) 71.29 -10.92% 2023-04-17 14:05:56
3 Moderna (MRNA) 143.90 -8.4% 2023-04-17 13:59:40
4 Canaan (CAN) 2.88 -7.74% 2023-04-17 13:43:42
5 Regis Corporation (RGS) 1.05 -7.08% 2023-04-17 07:08:08
6 Gevo (GEVO) 1.16 -6.85% 2023-04-17 13:54:54
7 Afya (AFYA) 12.62 -6.79% 2023-04-17 13:58:28
8 Orion Engineered Carbons S.A (OEC) 24.91 -6.14% 2023-04-16 19:06:08
9 MicroStrategy (MSTR) 314.78 -5.68% 2023-04-17 13:56:20
10 Bank of New York Mellon (BK) 43.79 -5.54% 2023-04-17 13:38:33

Winners today

1. Groupon (GRPN) – 11.33%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon jumping 11.33% to $4.18 on Monday, following the last session’s downward trend. NASDAQ jumped 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-7.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -213.9%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 33.6%, now sitting on 599.08M for the twelve trailing months.

More news about Groupon.

2. ImmunoGen (IMGN) – 7.8%

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with ImmunoGen rising 7.8% to $4.36 on Monday while NASDAQ rose 0.28% to $12,157.72.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.87.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -157.66%.

Yearly Top and Bottom Value

ImmunoGen’s stock is valued at $4.36 at 17:32 EST, way under its 52-week high of $6.63 and way higher than its 52-week low of $3.10.

More news about ImmunoGen.

3. Inovio Pharmaceuticals (INO) – 7.1%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals jumping 7.1% to $0.91 on Monday, following the last session’s downward trend. NASDAQ jumped 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -89.97%.

More news about Inovio Pharmaceuticals.

4. Enphase Energy (ENPH) – 7%

Enphase Energy, Inc., together with its subsidiaries, designs, develops, manufactures, and sells home energy solutions for the solar photovoltaic industry in the United States and internationally. The company offers semiconductor-based microinverter, which converts energy at the individual solar module level, and combines with its proprietary networking and software technologies to provide energy monitoring and control services. It also provides microinverter units and related accessories, an IQ gateway; IQ batteries; the cloud-based Enlighten monitoring service; storage solutions; and electric vehicle charging solutions; and design, proposal, permitting, and lead generation services. The company sells its solutions to solar distributors; and directly to large installers, original equipment manufacturers, strategic partners, and homeowners, as well as through its legacy product upgrade program or online store. Enphase Energy, Inc. was incorporated in 2006 and is headquartered in Fremont, California.

NASDAQ ended the session with Enphase Energy jumping 7% to $223.52 on Monday, following the last session’s downward trend. NASDAQ rose 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Enphase Energy has a trailing twelve months EPS of $2.76.

PE Ratio

Enphase Energy has a trailing twelve months price to earnings ratio of 80.99. Meaning, the purchaser of the share is investing $80.99 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 63.29%.

Volatility

Enphase Energy’s last week, last month’s, and last quarter’s current intraday variation average was 1.68%, 0.81%, and 2.58%.

Enphase Energy’s highest amplitude of average volatility was 2.08% (last week), 2.60% (last month), and 2.58% (last quarter).

Volume

Today’s last reported volume for Enphase Energy is 5596010 which is 36.85% above its average volume of 4089130.

Yearly Top and Bottom Value

Enphase Energy’s stock is valued at $223.52 at 17:32 EST, way below its 52-week high of $339.92 and way higher than its 52-week low of $128.67.

More news about Enphase Energy.

5. Viking Therapeutics (VKTX) – 6.67%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics rising 6.67% to $20.00 on Monday while NASDAQ jumped 0.28% to $12,157.72.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.67%.

Volume

Today’s last reported volume for Viking Therapeutics is 5145640 which is 26.47% above its average volume of 4068650.

Moving Average

Viking Therapeutics’s value is way higher than its 50-day moving average of $12.32 and way higher than its 200-day moving average of $6.47.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Viking Therapeutics’s EBITDA is -27.98.

More news about Viking Therapeutics.

6. Nikola (NKLA) – 6.6%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola rising 6.6% to $0.87 on Monday while NASDAQ jumped 0.28% to $12,157.72.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -128.56%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikola’s stock is considered to be overbought (>=80).

More news about Nikola.

7. M&T Bank (MTB) – 6.57%

M&T Bank Corporation operates as a bank holding company for Manufacturers and Traders Trust Company and Wilmington Trust, National Association that offer retail and commercial banking products and services in the United States. The company's Business Banking segment offers deposit, lending, cash management, and other financial services to small businesses and professionals. Its Commercial Banking segment provides deposit products, commercial lending and leasing, letters of credit, and cash management services for middle-market and large commercial customers. The company's Commercial Real Estate segment originates, sells, and services commercial real estate loans; and offers deposit, and credit services. Its Discretionary Portfolio segment provides deposits, securities, residential real estate loans, and other assets; and short and long term borrowed funds, as well as foreign exchange services. The company's Residential Mortgage Banking segment offers residential real estate loans for consumers and sells those loans in the secondary market; and purchases servicing rights to loans, and sub-services residential real estate loans for others. Its Retail Banking segment offers demand, savings, and time accounts; consumer installment loans, automobile and recreational finance loans, home equity loans and lines of credit, and credit cards; mutual funds and annuities; and other services. The company also provides trust and wealth management; fiduciary and custodial; insurance agency; institutional brokerage and securities; and investment management and advisory services; financial management, and planning, leasing, and financing services. It offers its services through banking offices, business banking centers, telephone and internet banking, and automated teller machines. M&T Bank Corporation was founded in 1856 and is headquartered in Buffalo, New York.

NYSE ended the session with M&T Bank jumping 6.57% to $124.25 on Monday, after two consecutive sessions in a row of gains. NYSE rose 0.43% to $15,668.34, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, M&T Bank has a trailing twelve months EPS of $11.53.

PE Ratio

M&T Bank has a trailing twelve months price to earnings ratio of 10.78. Meaning, the purchaser of the share is investing $10.78 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.22%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 58.4%, now sitting on 7.66B for the twelve trailing months.

Moving Average

M&T Bank’s value is below its 50-day moving average of $137.60 and way below its 200-day moving average of $160.31.

Yearly Top and Bottom Value

M&T Bank’s stock is valued at $124.25 at 17:32 EST, way under its 52-week high of $193.42 and way above its 52-week low of $110.00.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, M&T Bank’s stock is considered to be overbought (>=80).

More news about M&T Bank.

8. Li Auto (LI) – 6.19%

Li Auto Inc., through its subsidiaries, designs, develops, manufactures, and sells new energy vehicles in the People's Republic of China. The company provides Li ONE, a six-seat smart electric sport utility vehicle that is equipped with smart vehicle solutions, navigation on ADAS, and automatic emergency breaking functionalities. It also offers sales and after sales management, and technology development and corporate management services, as well as purchases manufacturing equipment. The company was formerly known as Leading Ideal Inc. and changed its name to Li Auto Inc. in July 2020. Li Auto Inc. was founded in 2015 and is headquartered in Beijing, China.

NASDAQ ended the session with Li Auto jumping 6.19% to $26.08 on Monday while NASDAQ rose 0.28% to $12,157.72.

: Xpeng stock jumps after new production platform unveiled, nio and Li Auto shares also rallyIt will make rapid advancements in technology available for our customers as standard, with faster software upgrades, stunning cost savings and elevated product experience. Shares of other China-based EV makers also got a lift, with Nio Inc.’s up 3.5% ahead of Monday’s open and Li Auto Inc.’s up 4.7%.

Earnings Per Share

As for profitability, Li Auto has a trailing twelve months EPS of $-0.31.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.71%.

More news about Li Auto.

9. Nio (NIO) – 5.77%

NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five, six, and seven-seater electric SUVs, as well as smart electric sedans. The company is also involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. In addition, it offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger, a fast-charging solution; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service, where it offers vehicle pick up, charging, and swapping services. Further, the company provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.

NYSE ended the session with Nio rising 5.77% to $9.81 on Monday while NYSE jumped 0.43% to $15,668.34.

: Xpeng stock jumps after new production platform unveiled, nio and Li Auto shares also rallyIt will make rapid advancements in technology available for our customers as standard, with faster software upgrades, stunning cost savings and elevated product experience. Shares of other China-based EV makers also got a lift, with Nio Inc.’s up 3.5% ahead of Monday’s open and Li Auto Inc.’s up 4.7%.

Earnings Per Share

As for profitability, Nio has a trailing twelve months EPS of $-1.31.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.79%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 62.2%, now sitting on 49.27B for the twelve trailing months.

Volatility

Nio’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.65%, a positive 0.42%, and a positive 3.23%.

Nio’s highest amplitude of average volatility was 3.88% (last week), 3.76% (last month), and 3.23% (last quarter).

Volume

Today’s last reported volume for Nio is 41784900 which is 4.6% below its average volume of 43800200.

More news about Nio.

10. Momo (MOMO) – 5.68%

Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. It operates Momo platform that includes its Momo mobile application, as well as various related properties, features, functionalities, tools, and services. The company's Momo mobile application connects people and facilitates interactions based on location and interests; and various recreational activities, including live talent shows, short videos, and social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke, and user participated reality shows. It also operates Tantan, a social and dating application, which enables users to find and establish romantic connections, and meet interesting people; and provides live video, quick chat, value-added, mobile marketing, and other services, as well as mobile games and audio chatrooms. In addition, it allows its platform's users to livestream a variety of content and activities that comprise talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Momo jumping 5.68% to $9.22 on Monday, after two sequential sessions in a row of gains. NASDAQ rose 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Momo has a trailing twelve months EPS of $1.14.

PE Ratio

Momo has a trailing twelve months price to earnings ratio of 8.08. Meaning, the purchaser of the share is investing $8.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.76%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.6%, now sitting on 12.7B for the twelve trailing months.

Yearly Top and Bottom Value

Momo’s stock is valued at $9.22 at 17:32 EST, way under its 52-week high of $11.54 and way above its 52-week low of $4.09.

More news about Momo.

Losers Today

1. Bionano Genomics (BNGO) – -17.75%

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics falling 17.75% to $0.90 on Monday, following the last session’s downward trend. NASDAQ jumped 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.21%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Bionano Genomics’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $0.90 at 17:32 EST, below its 52-week low of $0.98.

Volume

Today’s last reported volume for Bionano Genomics is 24356700 which is 307.41% above its average volume of 5978340.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 27.8M for the twelve trailing months.

More news about Bionano Genomics.

2. State Street Corporation (STT) – -10.92%

State Street Corporation, through its subsidiaries, provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, including custody, accounting, regulatory reporting, investor, and performance and analytics; middle office products, such as IBOR, transaction management, loans, cash, derivatives and collateral, record keeping, and client reporting and investment analytics; foreign exchange, and brokerage and other trading services; securities finance and enhanced custody products; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; performance, risk, and compliance analytics; and financial data management to support institutional investors. It also engages in the provision of portfolio management and risk analytics, as well as trading and post-trade settlement services with integrated compliance and managed data. In addition, the company offers investment management strategies and products, such as core and enhanced indexing, multi-asset strategies, active quantitative and fundamental active capabilities, and alternative investment strategies. Further, it provides services and solutions, including environmental, social, and governance investing; defined benefit and defined contribution; and global fiduciary solutions, as well as exchange-traded funds under the SPDR ETF brand. The company provides its products and services to mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1792 and is headquartered in Boston, Massachusetts.

NYSE ended the session with State Street Corporation falling 10.92% to $71.29 on Monday while NYSE jumped 0.43% to $15,668.34.

State street corporation (stt) Q1 earnings and revenues lag estimatesWhile State Street Corporation has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

Earnings Per Share

As for profitability, State Street Corporation has a trailing twelve months EPS of $7.19.

PE Ratio

State Street Corporation has a trailing twelve months price to earnings ratio of 9.92. Meaning, the purchaser of the share is investing $9.92 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.56%.

More news about State Street Corporation.

3. Moderna (MRNA) – -8.4%

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Moderna falling 8.4% to $143.90 on Monday, following the last session’s downward trend. NASDAQ rose 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Moderna has a trailing twelve months EPS of $20.31.

PE Ratio

Moderna has a trailing twelve months price to earnings ratio of 7.09. Meaning, the purchaser of the share is investing $7.09 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.27%.

More news about Moderna.

4. Canaan (CAN) – -7.74%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components primarily in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has a strategic cooperation with Northern Data AG in the areas of artificial intelligence development, blockchain technology, and datacenter operations. Canaan Inc. was founded in 2013 and is based in Beijing, the People's Republic of China.

NASDAQ ended the session with Canaan sliding 7.74% to $2.88 on Monday while NASDAQ rose 0.28% to $12,157.72.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $0.6.

PE Ratio

Canaan has a trailing twelve months price to earnings ratio of 4.8. Meaning, the purchaser of the share is investing $4.8 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.74%.

More news about Canaan.

5. Regis Corporation (RGS) – -7.08%

Regis Corporation owns, operates, and franchises hairstyling and hair care salons in the United States, Canada, Puerto Rico, and the United Kingdom. The company operates in two segments, Franchise Salons and Company-Owned Salons. Its salons provide haircutting and styling, including shampooing and conditioning; hair coloring; and other services, as well as sells various hair care and other beauty products. The company also offers mobile applications; and operates accredited cosmetology schools. Regis Corporation operates its salons primarily under the SmartStyle, Supercuts, Cost Cutters, Roosters, First Choice Haircutters, and Magicuts concepts names. As of June 30, 2022, the company operated 5,576 salons, such as 5,395 franchised salons, 105 company-owned salons, and 76 non-controlling ownership salons. Regis Corporation was founded in 1922 and is headquartered in Minneapolis, Minnesota.

NYSE ended the session with Regis Corporation dropping 7.08% to $1.05 on Monday, after two consecutive sessions in a row of losses. NYSE rose 0.43% to $15,668.34, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Regis Corporation has a trailing twelve months EPS of $-0.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1125.69%.

More news about Regis Corporation.

6. Gevo (GEVO) – -6.85%

Gevo, Inc. operates as a renewable fuels company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company offers renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Gevo sliding 6.85% to $1.16 on Monday, following the last session’s downward trend. NASDAQ rose 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Gevo has a trailing twelve months EPS of $-0.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17%.

More news about Gevo.

7. Afya (AFYA) – -6.79%

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.

NASDAQ ended the session with Afya sliding 6.79% to $12.62 on Monday while NASDAQ jumped 0.28% to $12,157.72.

Earnings Per Share

As for profitability, Afya has a trailing twelve months EPS of $0.85.

PE Ratio

Afya has a trailing twelve months price to earnings ratio of 14.85. Meaning, the purchaser of the share is investing $14.85 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.57%.

Sales Growth

Afya’s sales growth is 31.4% for the present quarter and 23.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Afya’s stock is considered to be oversold (<=20).

Volatility

Afya’s last week, last month’s, and last quarter’s current intraday variation average was 3.75%, 1.15%, and 2.67%.

Afya’s highest amplitude of average volatility was 3.75% (last week), 3.07% (last month), and 2.67% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Afya’s EBITDA is 7.95.

More news about Afya.

8. Orion Engineered Carbons S.A (OEC) – -6.14%

Orion Engineered Carbons S.A., together with its subsidiaries, produces and sells carbon black products in Germany, the United States, South Korea, Brazil, China, South Africa, the rest of Europe, and internationally. It operates through two segments, Specialty Carbon Black and Rubber Carbon Black. The company offers post-treated specialty carbon black grades for coatings and printing applications; high purity carbon black grades for the fiber industry; and various conductive carbon black grades for use in polymer and printing applications, as well as in silicon, non-woven textile, building material, battery electrodes metallurgical, agrochemical, and carbon brush applications. It also provides rubber carbon black products for applications in mechanical rubber goods under the PUREX brand, as well as in tires under the ECORAX brand name. The company was formerly known as Orion Engineered Carbons S.à r.l. and changed its name to Orion Engineered Carbons S.A. in July 2014. Orion Engineered Carbons S.A. was incorporated in 2011 and is headquartered in Houston, Texas.

NYSE ended the session with Orion Engineered Carbons S.A falling 6.14% to $24.91 on Monday, following the last session’s downward trend. NYSE rose 0.43% to $15,668.34, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Orion Engineered Carbons S.A has a trailing twelve months EPS of $1.62.

PE Ratio

Orion Engineered Carbons S.A has a trailing twelve months price to earnings ratio of 15.38. Meaning, the purchaser of the share is investing $15.38 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.26%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 19, 2023, the estimated forward annual dividend rate is 0.08 and the estimated forward annual dividend yield is 0.33%.

Moving Average

Orion Engineered Carbons S.A’s value is above its 50-day moving average of $24.45 and way higher than its 200-day moving average of $18.81.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 7% and positive 13.8% for the next.

Volume

Today’s last reported volume for Orion Engineered Carbons S.A is 894434 which is 63.88% above its average volume of 545758.

More news about Orion Engineered Carbons S.A.

9. MicroStrategy (MSTR) – -5.68%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy dropping 5.68% to $314.78 on Monday, following the last session’s downward trend. NASDAQ jumped 0.28% to $12,157.72, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-127.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -493.35%.

Sales Growth

MicroStrategy’s sales growth is negative 0.2% for the ongoing quarter and 1.7% for the next.

More news about MicroStrategy.

10. Bank of New York Mellon (BK) – -5.54%

The Bank of New York Mellon Corporation provides a range of financial products and services in the United States and internationally. The company operates through Securities Services, Market and Wealth Services, Investment and Wealth Management, and other segments. The Securities Services segment offers custody, trust and depositary, accounting, exchange-traded funds, middle-office solutions, transfer agency, services for private equity and real estate funds, foreign exchange, securities lending, liquidity/lending services, and data analytics. This segment also provides trustee, paying agency, fiduciary, escrow and other financial, issuer, and support services for brokers and investors. The Market and Wealth Services segment offers clearing and custody, investment, wealth and retirement solutions, technology and enterprise data management, trading, and prime brokerage services. This segment also provides integrated cash management solutions, including payments, foreign exchange, liquidity management, receivables processing and payables management, and trade finance and processing services. The Investment and Wealth Management segment offers investment management strategies and distribution of investment products, investment management, custody, wealth and estate planning, private banking, investment, and information management services. The Other segment engages in the provision of leasing, corporate treasury, derivative and other trading, corporate and bank-owned life insurance, renewable energy investment, and business exit services. It serves central banks and sovereigns, financial institutions, asset managers, insurance companies, corporations, local authorities and high net-worth individuals, and family offices. The company was founded in 1784 and is headquartered in New York, New York.

NYSE ended the session with Bank of New York Mellon sliding 5.54% to $43.79 on Monday while NYSE jumped 0.43% to $15,668.34.

Earnings Per Share

As for profitability, Bank of New York Mellon has a trailing twelve months EPS of $2.9.

PE Ratio

Bank of New York Mellon has a trailing twelve months price to earnings ratio of 15.1. Meaning, the purchaser of the share is investing $15.1 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.08%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jan 19, 2023, the estimated forward annual dividend rate is 1.48 and the estimated forward annual dividend yield is 3.19%.

Sales Growth

Bank of New York Mellon’s sales growth is 12.1% for the present quarter and 4.1% for the next.

Volatility

Bank of New York Mellon’s last week, last month’s, and last quarter’s current intraday variation average was 0.62%, 0.54%, and 1.32%.

Bank of New York Mellon’s highest amplitude of average volatility was 0.62% (last week), 1.17% (last month), and 1.32% (last quarter).

More news about Bank of New York Mellon.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *